"10.1371_journal.pone.0129766","plos one","2015-06-25T00:00:00Z","Quirijn R J G Tummers; Charlotte E S Hoogstins; Alexander A W Peters; Cor D de Kroon; J Baptist M Z Trimbos; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer; Katja N Gaarenstroom","Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Curadel, LLC, Worcester, Massachusetts, United States of America","Conceived and designed the experiments: QT CH CV JF AV KG. Performed the experiments: QT CH AP CK BT KG. Analyzed the data: QT CH KG. Contributed reagents/materials/analysis tools: JF. Wrote the paper: QT CH CK BT CV JF AV KG.","QRJG Tummers, CES Hoogstins, CD de Kroon, AAW Peters, JBMZ Trimbos, CJH van de Velde, AL Vahrmeijer and KN Gaarenstroom have no conflicts of interest or financial ties to disclose. JV Frangioni: FLARE technology is owned by Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. Dr. Frangioni has started three for-profit companies, Curadel, Curadel ResVet Imaging, and Curadel Surgical Innovations, which has optioned FLARE technology for potential licensing from Beth Israel Deaconess Medical Center. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","06","Quirijn R J G Tummers","QRJGT",9,TRUE,6,6,3,8,TRUE,TRUE,FALSE,0,NA,FALSE
